Special Issue Review Drugging RAS: Know the enemy

The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand. Authors: Bjoern Papke, Channing J. Der
Source: ScienceNOW - Category: Science Authors: Tags: Frontiers in Cancer Therapy Source Type: news

Related Links:

The physical and psychological side effects of breast cancer therapies can have substantial impact on survivors' physical and social functioning. Roughly half of the more than 3 million Americans alive with a history of breast cancer report adverse, function-degrading sequelae related to their oncologic treatments. Care delivery models for the timely delivery of rehabilitation services have been proposed yet limitedly vetted or implemented. These include the prospective surveillance model, procedure-linked referrals, survivorship care plans, and risk stratification. Patients' capacity to engage in the rehabilitative proces...
Source: American Journal of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Literature Review Source Type: research
CONCLUSIONS TCL-based immunotherapy has discrepant anti-tumor efficiency in different TNBC cell lines by PDL-1/PD interaction, providing the theoretical basis of TCL-based immunotherapy in TNBC. PMID: 30653481 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
by Craig Klugman, Ph.D. Jump to The Resident (Season 2; Episode 10): What would you do doctor?a>;Jump to The Good Doctor (Season 1; Episode 11): Ignoring patient rights; unnecessary risks; crisis planning; Jump to New Amsterdam (Season 1; Episode 11): Superutilizers and racism; Jump to Chicago Med (Season 4; Episode 11): Triage, gestational surrogacy conflicts; ends justifies the means The Resident (Season 2; Episode 10): What would you do doctor? As Hunter is released from prison on murder charges for killing patients with unneeded cancer therapy (sometimes on people without cancer), one of her victims is in the ED wit...
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: BioethicsTV Conflict of Interest Decision making End of Life Care Featured Posts Informed Consent professional ethics Public Health Reproductive Ethics Source Type: blogs
CONCLUSION: Powerful strategies able to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies. PMID: 30652649 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
After pioneering a targeted cancer therapy, he oversaw MD Anderson in Houston as it gained a reputation as the nation ’ s top cancer hospital.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Mendelsohn, John Deaths (Obituaries) University of Texas M D Anderson Cancer Center Erbitux (Drug) ImClone Systems Inc Source Type: news
Eli Lilly and Co said its cancer treatment Lartruvo failed to meet the main goal in a late-stage trial and it expects to take a charge in the first quarter of 2019, sending its shares down more than 2 percent in early trade.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
ACS NanoDOI: 10.1021/acsnano.9b00294
Source: ACS Nano - Category: Nanotechnology Authors: Source Type: research
Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy. Especially...
Source: BMC Complementary and Alternative Medicine - Category: Complementary Medicine Authors: Tags: Research article Source Type: research
Abstract Polymeric prodrug based on therapeutic nanomedicine has demonstrated great promise for effective tumor growth inhibition, however, the drawbacks of low drug-loading and weak micellar stability limit its application for clinical cancer therapy. Herein, a reduction-responsive starburst block copolymer prodrug CCP [β-cyclodextrin (β-CD)-PCPTXX-POEGMA, xx: SS or CC] has been developed for cancer therapy. And CCP is composed of β-CD-Br core with multiple reactive sites, as well as a diblock copolymer containing hydrophobic polymerized camptothecin (PCPT) prodrug chain and hydrophilic poly[(ethyl...
Source: Biomacromolecules - Category: Biochemistry Authors: Tags: Biomacromolecules Source Type: research
A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells — which can give rise to every cell type in the body and which can be grown indefinitely in the lab — into becoming mature T cells capable of killing tumor cells.The technique uses structures called artificial thymic organoids, which work by mimicking the environment of the thymus, the organ in which T cells develop from blood stem cells.T cells are cells of the immune system that fight infections, but also have the potential to eliminate cancer cells. The ability to create them from self-renewing pluripotent ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics